Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Buserelin

Our opinion on this compoundEstablished workhorse

42/100

Pioneering GnRH superagonist that defined a drug class but has largely been superseded as a research frontier

Look, buserelin earned its place in pharmacology history. The Sandow group at Hoechst AG published the original characterization in 1976, and within a few years this thing was demonstrating something genuinely surprising: continuous administration of a potent GnRH agonist could paradoxically shut down the very axis it initially stimulated. That biphasic mechanism, acute flare followed by profound receptor desensitization and downregulation, was not obvious, and buserelin was one of the first compounds to prove it worked in humans. The 1980 intranasal castration paper was legitimately a milestone.

That was roughly 45 years ago. The GnRH superagonist class is now thoroughly mapped. Leuprolide, goserelin, triptorelin, nafarelin, histrelin. Each with its own formulation advantages, depot options, and regulatory footprints. Buserelin’s structural chemistry, the D-serine tert-butyl substitution at position 6 and the C-terminal ethylamide, is textbook material at this point. The Gq/11-PLC signaling cascade, the receptor internalization kinetics, the castrate testosterone levels at steady state: all of it is worked out in detail across multiple labs and decades. Thats not a criticism of the molecule, its just the reality of where the science sits.

The differentiation problem is real. In most of the markets that matter to a North American or Australian investigator, buserelin isn’t approved. Leuprolide holds that ground. If you’re building a research program around HPG axis suppression, androgen deprivation biology, or GnRH receptor pharmacology, buserelin isn’t your default probe. It’s one of many options, and not the globally dominant one. The veterinary Receptal formulation (Intervet/MSD) shows up in livestock reproductive research, which is a niche with genuine utility but not the frontier.

What buserelin does have going for it: robust multi-indication clinical evidence across prostate cancer, endometriosis, uterine fibroids, breast cancer, precocious puberty, and ART protocols in roughly 40 jurisdictions. The translational signal from GnRH agonism to clinically meaningful endpoints is about as clean as it gets in endocrinology. Medical castration is a real, reproducible, durable pharmacological effect with decades of outcome data behind it. That counts for something on the evidence and translational axes even if it doesn’t make buserelin exciting.

We think the honest read here is: this is a mature, well-validated workhorse in a crowded class where it isnt the category leader in most key markets. For investigators already working in GnRH biology or hormone-dependent oncology, it’s a legitimate tool with a real evidence base. For anyone looking for novel mechanisms or underexplored research territory, theres nothing here that isn’t better addressed by asking why you’re not using leuprolide or, if you want genuine novelty, looking at GnRH antagonists (degarelix, relugolix) where the pharmacology is less worked-over and the research questions are fresher.

Novelty

20

Mechanism promise

38

In-category differentiation

25

Evidence quality

68

Translational signal

72

Research bench value

42

Rationale Buserelin is a 1976-vintage approved drug with a thoroughly characterized biphasic GnRH receptor mechanism, solid multi-indication clinical evidence, and real translational impact, but it competes in a crowded class where leuprolide and goserelin dominate globally, its US/Australia non-approval limits sourcing, and the core biology it exploits is genuinely mature. Novelty and differentiation scores drag the overall into the low 40s, which is accurate for a compound whose main contribution was historical.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic gonadotropin-releasing hormone superagonist nonapeptide with paradoxical chronic suppression of pituitary-gonadal axis through GnRH receptor desensitization and downregulation

A synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone bearing a D-serine(tert-butyl) substitution at position 6 and an ethylamide C-terminal modification, conferring 20- to 170-fold greater potency than native GnRH and resistance to enzymatic degradation, developed at Hoechst AG in the mid-1970s as one of the first clinically viable GnRH superagonists and now registered in approximately 40 jurisdictions for hormone-dependent prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, central precocious puberty, and pituitary downregulation in assisted reproduction protocols.

Abstract

Buserelin ([D-Ser(tBu)6,des-Gly-NH2-10]GnRH ethylamide; CAS 57982-77-1, free base; 68630-75-1, acetate salt) is a synthetic nonapeptide analog of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH, also designated luteinizing hormone-releasing hormone, LHRH) first described by Sandow and colleagues at Hoechst AG in 1976 and approved for clinical use in 1984 [1, 2]. The compound incorporates two structural modifications to native GnRH that collectively confer superagonist potency and metabolic stability: replacement of glycine at position 6 with D-serine bearing a tert-butyl ether on the side-chain hydroxyl, which eliminates the principal endopeptidase cleavage site and introduces conformational rigidity favorable to receptor binding; and replacement of the C-terminal glycinamide (position 10) with an ethylamide, which further resists carboxypeptidase degradation. The resulting peptide binds the type I GnRH receptor with affinity approximately 20- to 170-fold greater than native GnRH and produces a biphasic pharmacological response that is the mechanistic foundation for all clinical applications [3, 4]. Acute administration stimulates pituitary gonadotroph secretion of luteinizing hormone and follicle-stimulating hormone, producing transient elevations in gonadal steroid output (the “flare” phase, lasting 7 to 14 days). Chronic continuous administration produces homologous desensitization of the GnRH receptor through receptor internalization, uncoupling from Gq/11-phospholipase C signaling, and transcriptional downregulation of GnRH receptor expression, resulting in profound and sustained suppression of gonadotropin secretion and a hypogonadal state equivalent to surgical castration in both sexes [5, 6]. This medical castration is reversible on cessation of treatment. Buserelin was the first GnRH agonist demonstrated to achieve medical castration in humans via intranasal administration, an observation reported by Sandow and colleagues in 1980 that established the clinical viability of non-injectable GnRH agonist therapy [2]. The compound is registered in approximately 40 jurisdictions across Europe, the United Kingdom, Canada, New Zealand, South Africa, Latin America, and Asia, but is not approved in the United States or Australia. Registered indications include hormone-responsive prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and pituitary downregulation as an adjunct to controlled ovarian hyperstimulation in assisted reproduction [7, 8, 9]. The compound is additionally used off-label for central precocious puberty and as a component of gender-affirming hormone therapy. Pharmacokinetics are characterized by negligible oral bioavailability due to gastrointestinal peptidase degradation, approximately 2.5 to 3.3 percent intranasal bioavailability, and approximately 70 percent subcutaneous bioavailability [10]. The plasma elimination half-life is 50 to 80 minutes after intravenous or subcutaneous administration and approximately 1 to 2 hours after intranasal dosing. Protein binding is low (approximately 15 percent). Metabolism occurs principally through pyroglutamyl peptidase and chymotrypsin-like endopeptidase activity in the liver, kidneys, and gastrointestinal tract, with approximately 50 percent of the administered dose recovered unchanged in urine [10, 11]. Formulations include aqueous solution for subcutaneous injection and intranasal spray (requiring multiple daily administrations) and sustained-release subcutaneous implants providing 2- or 3-month depot delivery. The adverse-event profile is dominated by the pharmacological consequences of gonadal steroid suppression: hot flashes, reduced libido, erectile dysfunction or vaginal dryness, and long-term bone mineral density reduction. The initial flare phase carries specific risk in metastatic prostate cancer (bone pain exacerbation, spinal cord compression, ureteral obstruction), which is mitigated clinically by co-administration of an antiandrogen during the first 2 to 4 weeks of therapy. This monograph reviews the chemistry and synthesis, the biphasic GnRH receptor pharmacology, the comprehensive human pharmacokinetic record, the clinical evidence base across prostate cancer, endometriosis, uterine fibroids, breast cancer, precocious puberty, and assisted reproduction indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five GnRH agonist candidates against buserelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1395Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Pancragen

Our opinion on this compoundSingle-lab provenance

48/100

Single-consortium tetrapeptide with a genuinely novel beta cell epigenetics story undermined by complete absence of independent replication

Look, Pancragen sits in genuinely interesting territory. It’s a tetrapeptide from the Khavinson bioregulatory series, the same Saint Petersburg group behind Epithalon and a dozen other tissue-specific regulators, and the mechanism they propose is unlike anything else operating in the beta cell space right now. The claim is that this four-amino-acid sequence (Lys-Glu-Asp-Trp-NH2) penetrates cell nuclei, binds the major groove of double-stranded DNA at ACCT motif sequences in promoter regions, and directly upregulates the transcription factors governing pancreatic cell fate: PDX1, NGN3, PAX4, PAX6, FOXA2, NKX2-2, NKX6.1. PDX1 is the master regulator of beta cell identity, and stimulating its expression in aging or damaged islets is a legitimate and active target in diabetes biology. The mechanism, if real, would be extraordinary.

Here’s the problem: all of it comes from one group. The biophysical characterization via CD and molecular modeling, the organotypic culture studies showing tissue-specific growth stimulation at 0.05 ng/mL, the STZ rat pharmacology, the rhesus monkey IVGTT normalization in aged females after a 10-day IM course at 50 micrograms per day, the single clinical study in 33 elderly T2DM patients on glibenclamide background showing reduced fasting glucose and HOMA-IR. Every paper traces back to the same institute. Thats the defining characteristic of the entire Khavinson class, and Pancragen carries that liability fully.

What Pancragen has that Epithalon lacks is primate data showing genuine normalization of glucose disappearance rate and insulin dynamics during IVGTT, with partial persistence three weeks post-cessation. Thats not nothing. The clinical study also reported reduced 2-hour OGTT glucose and a mechanistically distinct profile versus glimepiride, suggesting the compound isn’t just pushing insulin secretion harder. But none of it has been independently replicated in any Western or non-affiliated Eastern lab. Not once.

What we like: the PDX1 and NGN3 upregulation story is mechanistically coherent, the tissue specificity claim is testable and specific enough to be falsifiable, and the aging-enhancement signal (effect more pronounced in aged cultures than young) fits a genuine geroprotective angle that differentiates it from standard insulin secretagogues. The primate and human signals at least suggest biological activity rather than noise.

What we dont like: the mechanism controversy is not minor. The idea that a tetrapeptide sequence-specifically binds genomic DNA in living cells and produces downstream transcriptional effects is theoretically plausible but has never been verified by independent structural biology or chromatin immunoprecipitation methods. The clinical study is too small and too poorly controlled to support firm conclusions. And the safety data is essentially the Khavinson group reporting no adverse events in underpowered datasets, which is not a toxicology program. For investigators studying pancreatic regeneration or the PDX1 axis in aging, this compound is worth tracking. It’s not ready to anchor a research program.

Novelty

58

Mechanism promise

60

In-category differentiation

55

Evidence quality

28

Translational signal

35

Research bench value

42

Rationale All evidence originates exclusively from Khavinson’s Saint Petersburg institute; the proposed direct DNA-binding mechanism targeting PDX1 and pancreatic differentiation factors is scientifically novel and testable but has never been independently verified, and the single clinical study at n=33 is too small and too uncontrolled to establish translational confidence. Scores well on novelty and mechanism promise but is sharply held back by single-source evidence and contested plausibility.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide bioregulator of pancreatic endocrine and exocrine cell differentiation and function

A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic modulator of pancreatic cell differentiation, glucose homeostasis, and beta cell functional recovery in aging and type 2 diabetes mellitus.

Abstract

Pancragen (Lys-Glu-Asp-Trp-NH2; KEDW) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (Russia) as a tissue-specific modulator of pancreatic endocrine and exocrine cell differentiation and function. The compound belongs to the Khavinson class of ultrashort (two to four amino acid) bioregulatory peptides, a pharmacological category defined by the hypothesis that short peptides penetrate cell nuclei, bind complementary DNA sequences in promoter regions through electrostatic and hydrogen-bond interactions, and modulate gene expression in a tissue-specific manner without engaging classical cell-surface receptors. Pancragen was derived from fractionation of bovine pancreatic tissue extracts; the tetrapeptide Lys-Glu-Asp-Trp was identified as the minimal active sequence responsible for the pancreotrophic activity of the parent extract preparation Suprefort. The compound has a molecular formula of C26H36N6O9 (free acid form) and a molecular weight of 576.60 g/mol. Physical-chemical characterization by ultraviolet-visible absorption spectroscopy, circular dichroism, and molecular modeling has demonstrated that the KEDW tetrapeptide binds double-stranded DNA in the major groove at sequences containing the ACCT motif, which is found in promoter regions of genes responsible for pancreatic cell differentiation and function [1]. The principal downstream molecular consequence of this interaction is upregulation of transcription factors that govern pancreatic endocrine cell fate, including PDX1 (the earliest marker of pancreatic progenitor cells and the master regulator of beta cell identity), NGN3, PAX6, PAX4, FOXA2, NKX2-2, and NKX6.1 [2, 3]. In organotypic pancreatic cell cultures from young and aged rats, Pancragen stimulated the expression of differentiation factors of both acinar cells (Pdx1, Ptf1a) and islet of Langerhans cells (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2), with the inducing effect more pronounced in aged cultures, consistent with a geroprotective mechanism [3]. Preclinical pharmacology in streptozotocin-induced diabetic rats demonstrated that oral Pancragen produced a pronounced hypoglycemic effect during the treatment period and that intramuscular administration normalized the adhesion properties of mesenteric capillary endothelium without modifying capillary permeability, suggesting homeostatic and endothelioprotective activity in early diabetes [4]. In a study of biological activity using immunoenzyme and high-performance liquid chromatography methods, the tetrapeptide modulated metabolic parameters characterizing apoptosis, including caspase-3 activity, in pancreatic beta cells and hepatocytes from streptozotocin-treated animals [5]. Primate studies in aged female rhesus monkeys demonstrated that a 10-day intramuscular course of Pancragen at 50 micrograms per day markedly increased the glucose disappearance rate, decreased basal insulin and C-peptide levels, and normalized glucose, insulin, and C-peptide dynamics during intravenous glucose tolerance testing, with partial persistence of these effects for three weeks after cessation of treatment [6, 7]. A comparative study in the same primate model demonstrated that Pancragen normalized insulin and C-peptide levels (suggesting recovery of disturbed glucose tolerance) while glimepiride produced a stronger but delayed blood-glucose-lowering effect without substantially affecting insulin secretion, indicating mechanistically distinct activity [7]. In a clinical study of 33 elderly patients with type 2 diabetes mellitus, Pancragen administered against a background of constant-dose glibenclamide significantly decreased fasting plasma glucose and glucose concentrations at two hours during oral glucose tolerance testing, reduced plasma insulin levels, and decreased the HOMA insulin resistance index; an additional glucose-lowering effect persisted for two weeks after cessation of Pancragen in 60 percent of patients who continued glibenclamide at unchanged doses [8]. Organotypic tissue culture studies confirmed that Pancragen at concentrations as low as 0.05 ng/mL stimulated tissue growth in pancreatic explants from both young and aged rats, with the stimulating effect tissue-specific (no effect on non-pancreatic tissue explants at the same concentration) [9]. The compound has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is marketed in Russia as a dietary supplement (Pancragen capsules) and is available internationally as a research-grade peptide from multiple suppliers. Formal toxicology studies meeting International Council for Harmonisation or FDA regulatory standards have not been published. The existing safety data, derived exclusively from the Khavinson research network, report no significant adverse events in preclinical or clinical studies at the doses and durations studied. This monograph reviews the chemistry, synthesis, and structural class of Pancragen; the epigenetic and transcriptional mechanism of action; the available pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology in cell culture, rodent, and primate models; the clinical evidence base in type 2 diabetes; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative pancreatic bioregulatory or beta cell-active compounds against Pancragen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1403Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Carbetocin

Our opinion on this compoundEstablished, active research

57/100

Approved uterotonic with a real biased-agonism profile and a credible CNS program in PWS

Carbetocin is one of those compounds that’s simultaneously very well understood and genuinely interesting, which makes rating it complicated. The uterotonic story is basically closed: the WHO CHAMPION trial enrolled nearly thirty thousand patients across 23 countries, established that heat-stable carbetocin 100 microgram IM was non-inferior to oxytocin 10 IU for preventing postpartum hemorrhage after vaginal birth, and cemented the compound in clinical guidelines specifically for settings where cold-chain storage is unavailable. You dont need more evidence than that. As a uterotonic research question, carbetocin has been answered.

What keeps it on the research radar is the molecular pharmacology. The two structural modifications – thioether substitution for the disulfide bridge, plus N-terminal deamination – were originally just stability engineering, but they ended up producing a functionally distinct GPCR profile. Carbetocin activates the Gq/phospholipase C/IP3 cascade with partial agonist efficacy while driving receptor internalization through a beta-arrestin-independent pathway that prevents receptor recycling. Thats a biased agonist profile, and it’s a real one. For investigators working on functional selectivity at class A GPCRs – an active enough subfield right now – carbetocin is a useful and somewhat underappreciated probe. You can isolate Gq-driven oxytocin receptor signaling without the beta-arrestin confound that native OXT brings, and the 40 to 85 minute half-life makes it substantially more tractable for in vivo neuroscience work than oxytocin’s three to four minute window.

The Prader-Willi syndrome program is the other angle worth watching. Acadia’s CARE-PWS Phase 3 trial (Kimonis et al. 2023) tested intranasal carbetocin at 3.2 to 9.6 mg three times daily in 130 participants aged 7 to 18 and reported clinically meaningful reductions in hyperphagia at the 3.2 mg dose. That’s a small trial by Phase 3 standards, but it’s the right design for a rare disease, and the hyperphagia signal was reasonably clean. The FDA issued a complete response letter to Acadia and further regulatory development has stalled, which dampens commercial enthusiasm. The biology doesn’t evaporate with the regulatory setback though. Intranasal OXTR agonism targeting hypothalamic satiety circuits and amygdala-driven anxiousness in a genetically defined population remains a mechanistically coherent research hypothesis.

Honestly, carbetocin scores where it does because it’s a compound that solved a real problem and then got interesting again for different reasons. We like the biased agonism profile as a bench tool, we like that the PWS signal is consistent enough to motivate further oxytocin-system CNS work, and the pharmacokinetics are just easier to work with than native oxytocin. What we don’t like is that the CNS research community hasn’t really caught up to the OXTR selectivity story yet, and outside the uterotonic indication the evidence base is thin. For a lab actively investigating OXTR pharmacology or hypothalamic circuit modulation in the context of metabolic or social behavior phenotypes, carbetocin belongs on the shelf. For most others it’s a reference compound and not a priority.

Novelty

38

Mechanism promise

55

In-category differentiation

52

Evidence quality

75

Translational signal

70

Research bench value

58

Rationale Carbetocin is a 1997-approved drug whose primary indication is essentially closed science after the 29,645-patient WHO CHAMPION trial, but the biased Gq/beta-arrestin OXTR pharmacology and the CARE-PWS Phase 3 intranasal CNS program inject genuine contemporary research interest above what compound age alone would suggest. Evidence and translational scores are elevated by the uterotonic evidence base; novelty and differentiation reflect the compound’s long clinical history.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting synthetic oxytocin receptor agonist with functional Gq selectivity

A 1-deamino-1-monocarba analog of oxytocin developed by Ferring Pharmaceuticals as a heat-stable uterotonic for the prevention of postpartum hemorrhage, distinguished from native oxytocin by enzymatic resistance, prolonged duration of action, functional selectivity at the Gq signaling pathway, and investigational application in Prader-Willi syndrome hyperphagia.

Abstract

Carbetocin (1-deamino-1-monocarba-(2-O-methyltyrosine)-oxytocin; CAS 37025-55-1; molecular formula C45H69N11O12S; molecular weight 988.16) is a synthetic long-acting analog of the neurohypophysial peptide oxytocin, developed for the prevention of uterine atony and postpartum hemorrhage following cesarean and vaginal delivery. The compound incorporates two critical structural modifications relative to native oxytocin: replacement of the disulfide bridge with a thioether (monocarba) linkage that confers resistance to disulfide reductases, and deamination of the N-terminal cysteine residue that eliminates aminopeptidase-mediated degradation. These modifications extend the plasma elimination half-life from approximately 3 to 4 minutes (oxytocin) to approximately 40 to 85 minutes (carbetocin), producing sustained uterotonic activity from a single 100 microgram intravenous or intramuscular injection [1, 2]. Carbetocin acts as a selective agonist at the oxytocin receptor (OXTR), a class A G protein-coupled receptor expressed on myometrial smooth muscle, myoepithelial cells of the mammary gland, and neuronal populations in the hypothalamus, amygdala, and brainstem. Molecular pharmacology studies have characterized carbetocin as a functionally selective (biased) Gq agonist: it activates the Gq/phospholipase C/inositol trisphosphate signaling cascade with partial agonist efficacy while inducing receptor internalization through a beta-arrestin-independent pathway that prevents receptor recycling to the plasma membrane [3]. This functional selectivity profile distinguishes carbetocin from native oxytocin (which recruits both Gq and beta-arrestin pathways) and from vasopressin V1a/V1b receptors at which carbetocin shows negligible agonist activity. The compound was first approved in 1997 (Duratocin, Pabal; Ferring Pharmaceuticals) for prevention of uterine atony following cesarean delivery and is now registered in more than 80 countries. The World Health Organization CHAMPION trial (Widmer et al. 2018), a 29,645-patient multinational randomized noninferiority study, demonstrated that a heat-stable formulation of carbetocin (100 microgram intramuscular) was noninferior to oxytocin (10 IU intramuscular) for prevention of postpartum hemorrhage after vaginal birth, establishing the compound as a viable alternative in settings where cold-chain storage is unavailable [4]. A second clinical development program, advanced by Acadia Pharmaceuticals, has evaluated intranasal carbetocin (3.2 to 9.6 mg three times daily) for the treatment of hyperphagia, anxiousness, and distress behaviors in Prader-Willi syndrome (PWS); the CARE-PWS Phase 3 trial (Kimonis et al. 2023) reported clinically meaningful improvements in hyperphagia at the 3.2 mg dose in 130 participants aged 7 to 18 years [5, 6]. Pharmacokinetics after intravenous administration show biphasic elimination with a terminal half-life of approximately 33 minutes; intramuscular administration produces a terminal half-life of approximately 55 minutes with bioavailability exceeding 80 percent [7]. The compound is well tolerated at registered doses; principal adverse events are nausea, vomiting, abdominal pain, flushing, headache, and transient hypotension, with a safety profile comparable to or more favorable than standard-dose oxytocin in pooled meta-analytic data [8, 9]. This monograph reviews the chemistry, synthesis, and structural modifications of carbetocin; the biased receptor pharmacology at the oxytocin receptor; comprehensive human pharmacokinetics; preclinical uterotonic and neurobehavioral pharmacology; the clinical evidence base across postpartum hemorrhage prevention and Prader-Willi syndrome indications; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative uterotonics and oxytocin-system compounds against carbetocin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1394Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Atosiban

Our opinion on this compoundEstablished, active research

48/100

Mature clinical tocolytic with genuine OTR probe value but low novelty ceiling

Look, atosiban is a genuinely interesting compound to think about, but interesting in the way a well-engineered clinical drug is interesting: methodically developed, narrowly targeted, and doing exactly what it was designed to do. Ferring reported it in 1986, got EU approval in 2000, and it’s been sitting comfortably as the only approved oxytocin receptor antagonist tocolytic for more than two decades. Thats a long runway. The novelty well dried up a while ago.

The mechanism is the most defensible part of the compound’s research case. Atosiban competitively blocks the oxytocin receptor and the vasopressin V1a receptor, suppressing the Gq/phospholipase C/IP3 signaling cascade in myometrial cells. Calcium release from the sarcoplasmic reticulum drops, calcium influx through voltage-gated channels drops, and the uterus quiets down. There’s also a secondary prostaglandin suppression angle via the decidua, which is mechanistically tidy. What’s notable is the receptor selectivity profile: high V1a affinity (Ki roughly 4.7 nmol/L), moderate OTR affinity (Ki roughly 397 nmol/L), negligible V1b and V2 activity. That’s a clean pharmacological tool. For labs studying OT/V1a receptor biology, atosiban gives you something reasonably selective with a clinical-grade manufacturing record behind it.

The evidence base is solid by clinical standards. The Phase III trials showed 59.6 percent of atosiban-treated women remaining undelivered at 7 days versus 47.7 percent in the beta-agonist arm, with a roughly 10-fold reduction in maternal cardiovascular adverse events. Over 156,000 treatment cycles in postmarketing and no serious maternal safety signals. That’s a mature clinical picture. What it isn’t is a neonatal-outcomes story; the Romero placebo-controlled trial didn’t demonstrate fetal benefit, which is partly why FDA never moved on it, and that’s a real limitation when thinking about how far the translational signal actually travels.

The IVF angle is where we see the most active current research interest. The logic is straightforward: uterine contractility during embryo transfer disrupts implantation, atosiban suppresses that contractility, pregnancy rates improve. Meta-analyses support the direction, though effect sizes and study quality vary. It’s a real secondary indication being actively studied, and we think it’s the most interesting thing happening with atosiban right now. Not groundbreaking, but genuinely worth watching for IVF-focused labs.

Here’s the thing: atosiban occupies a specific and well-defined niche. It’s the reference compound for clinical OTR antagonism, it has decent bench utility for studying uterine smooth muscle pharmacology and the OT/V1a axis, and it’s better differentiated from tocolytic alternatives than most people appreciate. But the novelty is low, the mechanism is thoroughly understood, and the research frontier has moved past it. A score in the high forties reflects a compound that earns its place in the library without pretending to be something it isn’t.

Novelty

28

Mechanism promise

42

In-category differentiation

55

Evidence quality

62

Translational signal

60

Research bench value

48

Rationale Atosiban is a 25-year-old EU-approved peptide with solid Phase III evidence and meaningful differentiation as the only approved oxytocin receptor antagonist tocolytic, but its low novelty, narrow indication focus, and well-characterized mechanism keep the overall score mid-range; the emergent IVF application adds some active-research credit without moving the needle substantially.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Competitive oxytocin receptor and vasopressin V1a receptor antagonist (cyclic nonapeptide tocolytic)

A synthetic cyclic nonapeptide analogue of oxytocin developed by Ferring Pharmaceuticals as a selective tocolytic for the management of preterm labor, distinguished from beta-adrenergic and calcium channel blocker tocolytics by its uterine-specific mechanism of action and favorable maternal cardiovascular safety profile.

Abstract

Atosiban (1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin; CAS 90779-69-4; molecular formula C43H67N11O12S2; molecular weight 994.19 g/mol) is a synthetic cyclic nonapeptide analogue of oxytocin that functions as a competitive antagonist at the oxytocin receptor and at the vasopressin V1a receptor, developed by Ferring Pharmaceuticals in Sweden and first reported in the literature by Melin et al. in 1986 [1]. The compound is the only oxytocin receptor antagonist approved for clinical tocolytic use, registered in the European Union since January 2000 under the trade name Tractocile and subsequently approved in approximately 67 countries for the acute management of preterm labor in pregnant women between 24 and 33 completed weeks of gestation. Atosiban is not approved by the United States Food and Drug Administration or in Japan; the absence of United States registration reflects Ferring’s assessment that the FDA requirement for placebo-controlled trials in United States patients would be ethically untenable rather than a formal regulatory rejection on efficacy or safety grounds [2]. At the molecular level, atosiban inhibits oxytocin-mediated activation of the Gq/phospholipase C/inositol 1,4,5-trisphosphate signaling cascade in myometrial cells, reducing intracellular calcium release from the sarcoplasmic reticulum and diminishing calcium influx through voltage-gated channels, thereby suppressing uterine smooth muscle contraction [3, 4]. The compound additionally suppresses oxytocin-mediated prostaglandin E2 and prostaglandin F2-alpha release from decidual tissue, a secondary mechanism that contributes to the tocolytic effect. Receptor binding studies report moderate affinity for the oxytocin receptor (Ki approximately 397 nmol/L) and high affinity for the vasopressin V1a receptor (Ki approximately 4.7 nmol/L), with negligible affinity at the V1b and V2 vasopressin receptor subtypes [5]. The onset of uterine quiescence after intravenous administration is rapid, with significant reduction in contraction frequency within 10 minutes. Pharmacokinetics are characterized by an initial half-life of 0.21 hours and a terminal half-life of 1.7 hours after intravenous infusion, a volume of distribution of 18.3 liters, plasma protein binding of 46 to 48 percent in pregnant women, and predominantly peptidase-mediated metabolism that is independent of the cytochrome P450 system [6]. The standard clinical dosing regimen comprises a 6.75 mg intravenous bolus followed by a loading infusion of 300 micrograms per minute for 3 hours and a maintenance infusion of 100 micrograms per minute for up to 45 hours, with total treatment not exceeding 48 hours and total dose not exceeding 330.75 mg. Phase III clinical trials demonstrated that 59.6 percent of atosiban-treated women remained undelivered without alternative tocolysis at 7 days compared to 47.7 percent in the beta-agonist comparator arm, with maternal cardiovascular adverse events occurring approximately 10-fold less frequently in the atosiban group (8.3 percent versus 81.2 percent) [7, 8]. The compound is well tolerated; nausea is the most common adverse event at 14 percent, and no serious maternal safety signals have been identified across more than 156,000 treatment cycles in postmarketing surveillance through 2005. A secondary research application in assisted reproduction has emerged from the observation that atosiban-mediated reduction in uterine contractility during embryo transfer may improve implantation rates in in vitro fertilization, with meta-analyses reporting significantly higher clinical pregnancy rates in atosiban-treated groups compared to controls [9, 10]. This monograph documents the chemistry, synthesis, and peptide pharmacology of atosiban; the oxytocin receptor and vasopressin V1a receptor antagonism in molecular and functional detail; the comprehensive pharmacokinetic record; the clinical evidence base across tocolytic and assisted reproduction indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling protocols; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five alternative tocolytic agents (nifedipine, ritodrine, indomethacin, magnesium sulfate, terbutaline) against atosiban on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1357Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Anamorelin

Our opinion on this compoundEstablished, active research

57/100

First approved oral ghrelin receptor agonist for cancer cachexia with rigorous Phase 3 lean mass data but contested functional endpoints and a cardiac liability

Look, anamorelin occupies a specific and genuinely useful niche that’s easy to undervalue because ghrelin biology feels like old news. It’s not. Cancer cachexia affects roughly 20-80% of patients depending on tumor type, and the mechanistic rationale for GHSR-1a agonism here is actually solid: ghrelin receptor stimulation drives appetite, GH secretion, and lean mass accretion through a well-characterized hypothalamic-pituitary-IGF-1 axis that’s demonstrably dysregulated in cachectic patients. The compound is a full agonist at subnanomolar affinity (Ki 0.70 nM, EC50 0.74 nM) with no antagonist activity up to 1000 nM, and the oral bioavailability plus 7-12 hour half-life give it pharmacokinetic properties that endogenous ghrelin’s 30-minute half-life can’t touch.

What we like: the ROMANA trial program is one of the better-designed cachexia programs ever executed. 979 patients, 93 sites, 19 countries, randomized double-blind placebo-controlled. That level of rigor is rare in the cachexia space, which has historically been riddled with small single-center studies. The lean body mass finding is solid and replicated across ROMANA 1 and ROMANA 2 (median gains of +1.10 kg and +0.75 kg versus placebo losses in each), and the Japanese ONO-7643-04 and ONO-7643-05 studies confirmed the pattern in a different tumor spectrum and patient population. Anamorelin became the first ghrelin receptor agonist approved anywhere in the world for cancer cachexia in December 2020 and has been commercially available as Adlumiz since April 2021. That’s a real milestone in a field starved for regulatory wins.

Here’s the thing though. The EMA refusal in 2017 is not a technicality. Both ROMANA trials failed the handgrip strength co-primary endpoint, and the EMA read that as the difference between improving body composition on paper and actually improving function. Thats a fair read. The disconnect between lean mass gains and functional strength suggests the anabolic signal, while real, doesnt fully translate to meaningful physical capacity in a cachectic patient. Whether that reflects population selection, endpoint choice, or a genuine pharmacological ceiling is still an open and productive research question.

Cardiac conduction effects deserve serious attention. Approximately 10.7% of patients in Japanese registration studies showed conduction abnormalities including PR interval, QRS, and QT prolongation, and the sodium channel-blocking activity is a genuine liability that constrains the safety envelope and should inform any combination design. The pronounced food effect, a 4-fold reduction in AUC when administered with food, is also a variable you’d need to control carefully in any pharmacokinetic study. CYP3A4 interactions are well-mapped; ketoconazole co-administration increases AUC by roughly 4-fold.

For investigators, anamorelin’s value is as the reference compound for oral GHSR-1a agonism in wasting conditions. MK-677 has broader research use but no regulatory approval in cachexia specifically and a messier evidence base in oncology populations. If you’re working on cancer-associated muscle wasting, the lean mass versus function dissociation, or GH-IGF-1 axis pharmacology in a clinical context, anamorelin is the approved comparator you’d want anchoring your design. We think it sits solidly in the established-active tier: not novel, not bleeding edge, but doing real work on a real problem with unusually rigorous clinical evidence for a compound of this class.

Novelty

42

Mechanism promise

50

In-category differentiation

65

Evidence quality

70

Translational signal

63

Research bench value

55

Rationale Anamorelin earns strong evidence and translational scores from the replicated ROMANA Phase 3 program and Japanese regulatory approval, but the ghrelin receptor mechanism is well-understood rather than novel, and the EMA rejection over failed handgrip strength endpoints signals a real gap between body composition and functional benefit that limits its ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-peptidic ghrelin receptor (GHSR-1a) agonist with orexigenic, anabolic, and growth hormone secretagogue activity

A small-molecule peptidomimetic ghrelin receptor agonist developed from the Novo Nordisk growth hormone secretagogue program, approved in Japan for the treatment of cancer cachexia in non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer, and investigated in osteosarcopenia and other wasting conditions.

Abstract

Anamorelin (ONO-7643, RC-1291, ST-1291) is a non-peptidic, orally active, centrally penetrant agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a), the endogenous receptor for ghrelin. Structurally derived from peptidomimetic optimization of the growth hormone-releasing peptide scaffold at Novo Nordisk and subsequently developed by Helsinn Healthcare and Ono Pharmaceutical, anamorelin binds the ghrelin receptor with subnanomolar affinity (Ki 0.70 nM) and produces full agonist activity in fluorescence imaging plate reader (FLIPR) calcium mobilization assays with an EC50 of 0.74 nM, comparable to endogenous ghrelin (Ki 0.58 nM, EC50 0.67 nM) [1]. No antagonist activity has been observed at concentrations up to 1000 nM. The compound is distinguished from endogenous ghrelin by oral bioavailability, a plasma elimination half-life of approximately 7 to 12 hours (compared to approximately 30 minutes for ghrelin), and the absence of peptidic instability. Pharmacodynamically, a single oral dose of 100 mg produces rapid and sustained elevation of circulating growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3), with secondary increases in appetite, caloric intake, and body weight observed on chronic dosing. The principal clinical application is cancer anorexia-cachexia syndrome (CACS). Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (ROMANA 1 and ROMANA 2), conducted in 979 patients with inoperable stage III or IV non-small cell lung cancer and cachexia across 93 sites in 19 countries, demonstrated that anamorelin 100 mg daily for 12 weeks significantly increased lean body mass (median change +1.10 kg versus -0.44 kg on placebo in ROMANA 1; +0.75 kg versus -0.96 kg in ROMANA 2; both P < 0.001) and body weight, with concurrent improvement in anorexia-cachexia symptoms and quality of life measures [2]. However, both trials failed to demonstrate statistically significant improvement in the co-primary endpoint of handgrip strength, a finding that became the basis for the European Medicines Agency refusal of marketing authorization in 2017 [3]. In Japan, where a separate Phase 2 trial (ONO-7643-04) in Japanese non-small cell lung cancer patients with cachexia and a Phase 3 open-label study (ONO-7643-05) in gastrointestinal cancer cachexia confirmed lean body mass and body weight increases, anamorelin received manufacturing and marketing approval from the Pharmaceuticals and Medical Devices Agency on December 11, 2020, as the first ghrelin receptor agonist approved worldwide for cancer cachexia [4]. It is marketed as Adlumiz tablets (50 mg) by Ono Pharmaceutical and has been available since April 2021 for the treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, or colorectal cancer. Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration 0.5 to 2.0 hours), a pronounced food effect (4-fold reduction in area under the curve when administered with food), hepatic metabolism predominantly through cytochrome P450 3A4 (CYP3A4) with minor contributions from CYP2C8 and CYP2D6, and fecal excretion of approximately 92 percent of the administered dose [5, 6]. The CYP3A4 dependence produces clinically significant drug-drug interaction potential with strong CYP3A4 inhibitors (ketoconazole increases the AUC of anamorelin by approximately 4-fold). The compound depresses cardiac conduction and has sodium channel-blocking activity; prolongation of the PR interval, QRS complex, and QT interval has been observed in clinical trials, with a frequency of approximately 10.7 percent for conduction system abnormalities in Japanese registration studies [7, 8]. Contraindications include congestive heart failure, recent myocardial infarction or angina pectoris, and severe cardiac conduction defects. The most frequent adverse events are hyperglycemia (5 to 6 percent overall, substantially higher in patients with pre-existing diabetes), elevated gamma-glutamyl transpeptidase, and gastrointestinal symptoms. This monograph reviews the chemistry, synthesis, and structural pharmacology of anamorelin; the ghrelin receptor mechanism in molecular and physiological detail; comprehensive pharmacokinetics including food effect and CYP3A4 interaction; the preclinical pharmacology in rat, pig, and tumor xenograft models; the clinical evidence base across the ROMANA program, Japanese registration studies, and the osteosarcopenia indication; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five cachexia and wasting treatment candidates (ibutamoren, enobosarm, megestrol acetate, mirtazapine, and espindolol) against anamorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1417Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Octreotide

Our opinion on this compoundEstablished workhorse

52/100

The canonical SSTR2-selective reference compound, clinically mature with real bench utility but little frontier novelty

Look, octreotide is one of those compounds where the sheer weight of clinical evidence almost works against it as a research target. Bauer and colleagues at Sandoz synthesized SMS 201-995 in 1982, the FDA approved it in 1988, and by now the somatostatin receptor subtype 2 pharmacology it illuminated has been exhaustively characterized. We know the binding kinetics cold: Ki approximately 0.4 to 0.6 nanomolar at SSTR2, roughly 7 nanomolar at SSTR5, negligible at SSTR1 and SSTR4. The Gi-coupled downstream cascade, adenylyl cyclase inhibition, reduced cAMP, suppression of GH and the splanchnic peptide circus, its all textbook material at this point.

What octreotide genuinely has going for it is bench value as a reference probe. If you’re doing SSTR subtype selectivity work, you need octreotide in the comparison panel. The PROMID trial data (Rinke et al. 2009, HR 0.34, p equal to 0.000072 on time to tumor progression in midgut NETs) is clean and credible. The PK record after subcutaneous dosing, peak at 25 to 30 minutes, bioavailability near 100 percent, t1/2 roughly 90 to 120 minutes, is mature enough to serve as a reference standard for half-life extension strategies in the cyclic peptide space. The 2020 oral Mycapssa approval is genuinely interesting from a formulation-science angle, even if the compound underneath is old news.

Here’s the thing though: the research frontier in the somatostatin axis has moved. Pasireotide, with its broader SSTR1/2/3/5 profile, is the more interesting pharmacological object for investigators interested in Cushing’s disease and escape mechanisms. Lu-177 DOTATATE has repositioned the entire NET field around theranostic radiopharmaceuticals, and the octreotide scaffold underpins that ligand family as a structural starting point rather than a target in its own right. Paltusotine is the oral non-peptide SSTR2 agonist that will eventually displace octreotide in clinical maintenance, and it raises much more interesting SAR questions. Octreotide itself is mostly the molecule you reach for when you need to define what SSTR2-selective engagement looks like, not the molecule anyone is running a serious exploratory program around in 2026.

We think its place in a research library is legitimate but specific: its a comparator, a reference point, a structural ancestor. The evidence quality and translational signal scores are high because decades of human data dont lie. But the novelty and mechanism scores honestly reflect that theres very little left to discover here. Serious bench investigators in the somatostatin space will use it; they just wont be excited about it.

Novelty

22

Mechanism promise

38

In-category differentiation

50

Evidence quality

78

Translational signal

78

Research bench value

62

Rationale Octreotide scores strongly on evidence and translational signal because it is an FDA-approved drug with replicated phase 3 data and decades of clinical use, but those same facts drive novelty and mechanism scores to the floor. The compound is 40+ years old and the SSTR2 pharmacology it opened is now thoroughly characterized; the primary research question for the field has shifted to broader-subtype agents, radiolabeled conjugates, and oral non-peptide agonists, leaving octreotide as an indispensable reference probe rather than a live research frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic cyclic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 and 5

A disulfide-bridged octapeptide analog of hypothalamic somatostatin-14 developed at Sandoz as SMS 201-995, distinguished from the native hormone by a 30-fold increase in inhibition of growth hormone release relative to insulin suppression and an elimination half-life extended from under 3 minutes to approximately 100 minutes after subcutaneous administration.

Abstract

Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1390Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Mecasermin rinfabate

Our opinion on this compoundEstablished workhorse

44/100

Elegant but withdrawn IGF-1 binary complex whose science held up while the market window closed

Look, mecasermin rinfabate is one of those compounds where the science was genuinely solid and the story ended for the wrong reasons. The binary complex approach (pairing rhIGF-1 with rhIGFBP-3 in equimolar ratios to replicate the dominant physiological form of circulating IGF-1) was clever when Celtrix developed it in the late 1990s. The pharmacokinetic rationale holds up: free IGF-1 clears in roughly 10 to 20 minutes, while the binary complex extends that to 13 to 21 hours by associating with endogenous acid-labile subunit to reconstitute the normal ternary reservoir. That’s real pharmacology, not marketing.

What we dont like is that by 2026, this is a 20-year-old story. iPLEX was FDA-approved in December 2005 for severe primary IGF-1 deficiency, briefly marketed, then pulled in March 2007 following patent litigation with Tercica over Increlex. The withdrawal was legal, not scientific; the mechanism was never challenged. But that distinction doesnt help much from a research calendar standpoint. Mecasermin rinfabate has spent nearly two decades as a research-grade artifact rather than an active pharmaceutical. The IGF-1/IGFBP-3 axis biology is textbook at this point, and the clinical population it originally served remains Increlex territory.

The post-withdrawal programs are worth knowing about but dont dramatically change the picture. The ALS push was scientifically motivated: IGF-1 signals through PI3K/Akt and MAPK pathways in motor neurons, and rescue effects in SOD1 transgenic rodent models were reproducible enough to justify clinical evaluation. The trial results were inconclusive, though, and the program stalled. The neonatal work around retinopathy of prematurity is more alive; there’s genuine signal in small studies of IGF-1 supplementation in preterm neonates, and the biology (IGF-1 as a developmental cue for vascular normalization in the immature retina) is real. The evidence base remains limited, mostly single-center or small-consortium, without the multi-lab replication a serious bench program needs to lean on.

As a research tool, rinfabate has one concrete advantage over free rhIGF-1: the extended pharmacokinetics let you study sustained IGF-1 axis activation without the hypoglycemia confound that complicates mecasermin studies. That’s real bench utility for groups working on IGF-1’s role in neurodegeneration or neonatal vascular biology. But its not irreplaceable; mecasermin with careful dosing protocols covers most of the same biology, and downstream pathway probes (PI3K inhibitors, IGF-1R knockdowns) are often more useful for mechanistic work anyway. For most investigators, mecasermin rinfabate is an interesting historical footnote rather than a primary tool. The original pharmacological concept was genuinely elegant. The research window just passed.

Novelty

28

Mechanism promise

42

In-category differentiation

45

Evidence quality

58

Translational signal

52

Research bench value

40

Rationale Mecasermin rinfabate solved a genuine PK problem with physiological elegance and earned FDA approval, but a 2007 patent-litigation withdrawal left it dormant for nearly two decades; the ALS and neonatal successor programs have produced modest, unreplicated signal that keeps it interesting for niche investigators without elevating it to active-research priority.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Recombinant human insulin-like growth factor-1 and insulin-like growth factor binding protein-3 equimolar binary complex (rhIGF-1/rhIGFBP-3)

A recombinant equimolar binary protein complex of human IGF-1 and its principal binding protein IGFBP-3, developed by Insmed as iPLEX for subcutaneous replacement therapy in severe primary IGF-1 deficiency and subsequently investigated in amyotrophic lateral sclerosis and complications of extreme prematurity.

Abstract

Mecasermin rinfabate (International Nonproprietary Name; brand name iPLEX) is a pharmaceutical-grade equimolar binary complex of recombinant human insulin-like growth factor-1 (rhIGF-1, 70 amino acids, 7,649 Da) and recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3, 264 amino acids, approximately 28,700 Da unglycosylated), produced in Escherichia coli expression systems and formulated for subcutaneous injection at a combined molecular weight of approximately 36,381 daltons. The complex was designed to replicate the physiological binary association of IGF-1 with its most abundant circulating binding protein, thereby extending the plasma half-life of administered IGF-1 from approximately 10 to 20 minutes (free rhIGF-1) to approximately 13 to 21 hours (complexed form), reducing hypoglycemic risk relative to unbound IGF-1, and enabling once-daily subcutaneous dosing in contrast to the twice-daily regimen required for mecasermin (rhIGF-1 alone, marketed as Increlex). Upon subcutaneous administration, the binary complex associates with endogenous acid-labile subunit (ALS) to form the approximately 150 kDa ternary complex that represents the principal physiological reservoir of circulating IGF-1, thereby normalizing the IGF-1 axis in patients with deficient endogenous production.

The compound received United States Food and Drug Administration approval on December 12, 2005 (NDA 021884) for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The approved dose range was 0.5 to 2.0 mg/kg administered once daily by subcutaneous injection, titrated to achieve physiological IGF-1 levels measured 8 to 18 hours post-dose. Clinical development was conducted in two cohort studies enrolling 36 children and adolescents with primary IGFD, predominantly growth hormone receptor deficiency (Laron syndrome), demonstrating statistically significant dose-dependent increases in height velocity from a pre-treatment baseline of approximately 3 to 4 cm/year to 6 to 9 cm/year during the first year of treatment.

The commercial trajectory of mecasermin rinfabate was truncated by patent litigation. In March 2007, Insmed Incorporated settled a patent infringement action brought by Tercica (the manufacturer of mecasermin/Increlex) by agreeing to withdraw iPLEX from the United States market for all short stature indications and to abandon its European regulatory application for these uses. The settlement extinguished the primary commercial indication. Insmed subsequently investigated mecasermin rinfabate in amyotrophic lateral sclerosis (ALS) under both clinical trial and compassionate-use frameworks; a Phase II randomized controlled trial in 330 ALS patients failed to demonstrate benefit on muscle strength, need for tracheostomy, or survival at the end of a two-year treatment period. More recently, the rhIGF-1/rhIGFBP-3 complex (under the development name of the successor product) has been investigated by Shire (now Takeda) and collaborators in extremely preterm infants for prevention of retinopathy of prematurity and other complications of prematurity, with a Phase 2 randomized controlled trial (NCT01096784) demonstrating a 53 percent decrease in severe bronchopulmonary dysplasia but no reduction in retinopathy of prematurity severity.

The pharmacology of mecasermin rinfabate is that of its constituent IGF-1 moiety acting through the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase that activates the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase (MAPK/ERK) signaling cascades to promote linear growth, cellular proliferation, differentiation, and survival. The IGFBP-3 moiety serves as a pharmacokinetic modulator, extending half-life and buffering against acute hypoglycemia, while also exerting IGF-independent effects including proapoptotic activity through nuclear receptor interactions and antiproliferative signaling in certain cellular contexts. The principal adverse events at approved doses are hypoglycemia (31 percent), headache (22 percent), arthralgia, injection site reactions, and lymphadenopathy. Safety data beyond 21 months of continuous treatment have not been established. This monograph reviews the molecular composition, development history, mechanism of action, pharmacokinetics, clinical evidence base across all studied indications, handling considerations, adverse-event profile, and a comparative assessment of five IGF-1 axis therapeutics against mecasermin rinfabate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1423Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Maritide

Our opinion on this compoundNovel frontier

76/100

First-in-class bispecific antibody-peptide conjugate betting on GIPR antagonism with compelling Phase 2 weight-loss signal

Look, the incretin space is crowded, but maritide is doing something genuinely different from every other molecule in it. While tirzepatide bets that GIP receptor agonism enhances GLP-1 action, maridebart cafraglutide takes the opposite position: block GIPR and see what happens when GLP-1R gets all the floor. The fact that both approaches produce serious weight loss in humans is itself a research finding worth sitting with, because it says something important and still-contested about how GIP signaling actually works in metabolic disease. That mechanistic debate is live, and maritide is one of the primary instruments for settling it.

The molecular architecture earns its novelty points on its own terms. This isnt a dual peptide agonist or a bispecific small molecule. Its a fully human IgG2 monoclonal antibody with two covalently attached GLP-1 agonist peptide analogues, which gives a terminal half-life around 21 days after subcutaneous dosing. Thats roughly three times longer than semaglutide’s weekly profile, and it represents a distinct pharmacological regime that lets you ask different questions about receptor occupancy duration, downstream signaling adaptation, and what chronic receptor blockade looks like across adipose versus central tissue compartments.

The Phase 2 data (NCT05669599, 592 adults, 52 weeks) is the most interesting part of the current evidence base. Up to 20 percent weight loss in participants without type 2 diabetes, HbA1c reductions of up to 2.2 percentage points, and a no-plateau finding at 52 weeks. Most GLP-1 agents show flattening curves by mid-study. If that non-plateau signal holds in Phase 3, thats a real clinical differentiation. The Phase 2 also reported fat-preferential mass loss without clinically significant bone mineral density changes, which addresses a concern that has been following the whole class since semaglutide’s lean mass signal appeared in STEP. The gastrointestinal tolerability data at the dose-escalated arms is also more favorable than earlier versions of the protocol.

What we don’t like: this is still a single-developer compound with no independent academic replication of the core GIPR antagonism mechanism. The downstream biology of chronically blocking GIP while agonizing GLP-1R at high receptor occupancy is not fully worked out. Amgen initiated the MARITIME Phase 3 program in 2025, but primary readouts arent expected until early 2027, so the evidence base is going to sit at Phase 2 for a while. Retatrutide and tirzepatide both have further-developed clinical profiles right now, and whether GIPR antagonism matches or beats dual agonism is genuinely unanswered.

For researchers working in incretin pharmacology, body composition biology, or antibody-peptide conjugate engineering, maritide is one of the more interesting compounds in the current landscape. The bispecific format alone is worth studying as an architecture. We think the GIPR antagonism angle is the more intellectually interesting mechanistic bet in the space right now, and the Phase 2 signal gives real reason to follow Phase 3 closely.

Novelty

82

Mechanism promise

84

In-category differentiation

84

Evidence quality

62

Translational signal

70

Research bench value

60

Rationale The bispecific IgG2-peptide conjugate format and the GIPR antagonism pharmacological bet (opposite to tirzepatide’s agonism) earn genuine novelty and differentiation scores; evidence and translational axes are constrained by the Phase 2-only evidence base, with MARITIME Phase 3 readouts not expected until early 2027.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism

A first-in-class bispecific antibody-peptide conjugate developed at Amgen that pairs a fully human monoclonal glucose-dependent insulinotropic polypeptide receptor antagonist antibody with two covalently linked glucagon-like peptide 1 analogue agonist peptides, yielding a long-acting once-monthly injectable for chronic weight management distinguished from existing incretin therapeutics by simultaneous GIP receptor blockade and an approximately 21-day elimination half-life.

Abstract

Maridebart cafraglutide (MariTide; development code AMG 133) is a first-in-class bispecific peptide-antibody conjugate engineered at Amgen by covalent attachment of two glucagon-like peptide 1 (GLP-1) receptor agonist peptide analogues to a fully human immunoglobulin G2 (IgG2) monoclonal antibody that functions as a potent antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). The molecule was designed to exploit the additive weight-loss pharmacology of simultaneous GLP-1 receptor (GLP-1R) activation and GIP receptor blockade, a mechanistic combination that in preclinical diet-induced obese mouse and cynomolgus monkey models produced greater body-weight reduction than either moiety alone. In cell-based functional assays the compound demonstrates GLP-1R agonist activity with EC50 values of 24.4 picomolar (human), 5.7 picomolar (cynomolgus monkey), 2.4 picomolar (rat), and 123 picomolar (mouse), and GIPR antagonist activity with IC50 values of 46.4 nanomolar (human), 26.5 nanomolar (cynomolgus monkey), and 822.3 nanomolar (rat) [1, 2]. The antibody scaffold confers a terminal elimination half-life of approximately 21 days in humans after subcutaneous administration, approximately three-fold longer than the longest-acting approved once-weekly GLP-1 receptor agonists, and supports once-monthly or less frequent dosing [1]. In a Phase 1 randomized, double-blind, placebo-controlled single- and multiple-ascending-dose study (NCT04478708) in 163 adults with obesity, maridebart cafraglutide produced dose-dependent weight loss of up to 14.5 percent at 12 weeks with weight loss maintained for up to 150 days after the final dose, accompanied by an acceptable safety and tolerability profile in which gastrointestinal adverse events (nausea, vomiting) were predominantly mild and transient [1]. A Phase 2 dose-ranging study (NCT05669599) in 592 adults with obesity with or without type 2 diabetes randomized to subcutaneous maridebart cafraglutide at 140, 280, or 420 mg every four weeks or 420 mg every eight weeks versus placebo for 52 weeks demonstrated mean weight loss of 12.3 to 20 percent in participants without type 2 diabetes and 8.4 to 17 percent in participants with type 2 diabetes, with HbA1c reductions of up to 2.2 percentage points, without evidence of a weight-loss plateau at 52 weeks [3, 4]. The Phase 2 study further reported no clinically significant changes in bone mineral density and body-composition data indicating that the majority of weight lost was fat mass rather than lean tissue. Gastrointestinal adverse events were the most common treatment-emergent events and were mitigated by dose escalation from a lower starting dose; discontinuation rates due to gastrointestinal events were approximately 8 percent with dose escalation compared with 12 to 27 percent without [3, 4]. Amgen initiated the Phase 3 MARITIME program in 2025, comprising chronic weight management trials (MARITIME-1 in obesity without type 2 diabetes, MARITIME-2 in obesity with type 2 diabetes) with planned 72-week treatment duration and primary readouts expected in early 2027, as well as planned Phase 3 cardiovascular outcomes, heart failure, and obstructive sleep apnea studies [5, 6]. The compound is not approved by any regulatory authority as of the monograph date. This monograph documents the molecular design and structural biology of the peptide-antibody conjugate; the dual-receptor pharmacology at GLP-1R and GIPR in molecular and cellular detail; the preclinical pharmacology in rodent and primate models; the comprehensive human pharmacokinetic record; the clinical evidence base across Phase 1 and Phase 2 obesity and type 2 diabetes endpoints; sourcing and handling considerations; stack-interaction implications; adverse-event profile; and a comparative assessment of five incretin-class obesity therapeutics against maridebart cafraglutide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1412Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Pemvidutide

Our opinion on this compoundNovel frontier

70/100

Balanced GLP-1/GCGR dual agonist with exceptional Phase 2b MASH biopsy data and FDA Breakthrough Therapy Designation

Look, the GLP-1 receptor agonist story has been told. Semaglutide changed metabolic medicine. Tirzepatide added GIP and extended the effect. What pemvidutide does is point the second receptor somewhere different: straight at the liver. The glucagon receptor axis drives hepatic fatty acid beta-oxidation and suppresses de novo lipogenesis directly, producing a pharmacology that is mechanistically suited to MASH in a way that a GLP-1-only agent isn’t. The 1:1 GLP-1R/GCGR co-agonism ratio is deliberate: glucagon raises glucose, GLP-1 counters it, and the net glycemic result is approximately neutral at therapeutic doses. That’s an elegant design choice that lets the compound go after the liver without glycemic misfires in a metabolically fragile population.

The EuPort glycolipid conjugation is worth noting on its own terms. The 18-carbon diacid alkyl chain creates near-quantitative but transient albumin binding that extends plasma half-life to weekly dosing without a titration requirement. That’s a real formulation engineering advance, and it’s structurally distinct from the fatty diacid chemistry semaglutide uses, making it an interesting probe for half-life extension strategy comparisons as well.

The clinical signal is what puts this compound on the priority list. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 1.8 mg weekly produced a 68.5% relative reduction in liver fat by MRI-PDFF at 12 weeks, extending to 75.2% at 24 weeks. Those are not modest numbers. The Phase 2b IMPACT trial in 212 biopsy-confirmed MASH patients with F2-F3 fibrosis is the bigger story: 59.1% MASH resolution without fibrosis worsening at 1.2 mg versus 19.1% for placebo (p less than 0.0001). For context, resmetirom’s MASH approval was built on roughly 26% histological response rates. The FDA recognized the signal: Breakthrough Therapy Designation was granted in January 2026, alongside Fast Track for both MASH and AUD.

On the obesity side, the MOMENTUM trial showed 15.6% weight loss at 48 weeks, with 78.1% of that loss attributable to fat mass. Thats competitive with tirzepatide at comparable durations, though head-to-head data doesnt exist. The AUD indication is genuinely novel and the preclinical alcohol preference model is interesting, but human evidence there is still thin.

What we like: the GCGR-directed liver mechanism is real and well-differentiated from approved agents, the IMPACT biopsy data is exceptional for a Phase 2b readout, and BTD is a serious signal that the FDA considers the data compelling. What we don’t like: Phase 3 hasn’t run yet, Altimmune is a smaller shop operating in a space dominated by Novo Nordisk and Lilly, and survodutide plus other GLP-1/GCGR programs are actively competing. The evidence base is strong for its stage but not yet replicated across independent groups. For investigators studying MASH biology, incretin co-agonism, or liver-targeted metabolic pharmacology, this is one of the more interesting compounds in active clinical development right now.

Novelty

68

Mechanism promise

80

In-category differentiation

70

Evidence quality

62

Translational signal

77

Research bench value

60

Rationale Pemvidutide scores high on mechanism (deliberate 1:1 GLP-1R/GCGR co-agonism with liver-directed hepatic fat oxidation) and translational signal (59.1% biopsy-confirmed MASH resolution vs 19.1% placebo in the IMPACT Phase 2b, BTD granted January 2026). Pre-Phase 3 status, a competitive incretin landscape, and single-sponsor clinical data limit the ceiling on novelty and evidence scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Balanced dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist peptide with glycolipid half-life extension

A 29-amino-acid unimolecular peptide engineered for equipotent GLP-1 and glucagon receptor co-agonism, conjugated to a proprietary glycolipid moiety for weekly subcutaneous dosing, under clinical development for metabolic dysfunction-associated steatohepatitis, obesity, and alcohol use disorder.

Abstract

Pemvidutide (ALT-801; CAS 2538014-94-5; UNII A35F525WBG; molecular formula C182H275N39O54; molecular weight 3873.42 g/mol) is a synthetic 29-amino-acid peptide that functions as a balanced (1:1) dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed by Altimmune, Inc. (Gaithersburg, Maryland) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The compound incorporates sequence elements derived from both GLP-1 and glucagon and is conjugated to an 18-carbon diacid alkyl chain through a proprietary glycosidic linkage (designated EuPort), which provides near-quantitative but transient binding to serum albumin and extends the plasma half-life to a duration consistent with once-weekly subcutaneous administration without dose titration [1, 2]. The dual receptor mechanism differentiates pemvidutide from selective GLP-1 receptor agonists such as semaglutide and liraglutide: GLP-1R activation suppresses appetite through hypothalamic and brainstem satiety circuits, delays gastric emptying, and improves glycemic control, while GCGR activation directly stimulates hepatic fatty acid beta-oxidation, suppresses de novo lipogenesis, and increases energy expenditure through thermogenic pathways, producing a composite antisteatotic and weight-reducing pharmacology that is mechanistically suited to liver-predominant metabolic disease [3, 4, 5]. In the translational AMLN diet-induced obese mouse model of NASH, pemvidutide at 10 nmol/kg subcutaneous produced approximately 25 percent body weight reduction, significant reductions in liver triglycerides, galectin-3, collagen type 1 alpha 1, and NAFLD Activity Score, with efficacy exceeding that of semaglutide and elafibranor at equimolar doses on composite histological endpoints [6]. Clinical development has advanced through Phase 1 studies (NCT04561245, 100 subjects), Phase 1b/2a studies in MASLD (NCT05006885, 95 subjects; NCT05292911, 64 subjects), the Phase 2 MOMENTUM obesity trial (391 subjects, 48 weeks), and the Phase 2b IMPACT trial in biopsy-confirmed MASH (NCT05989711, 212 subjects) [1, 7, 8, 9, 10]. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 12 weeks of pemvidutide at 1.8 mg weekly produced a 68.5 percent relative reduction in liver fat content by MRI-proton density fat fraction versus 4.4 percent for placebo (p < 0.001), with 55.6 percent of treated subjects achieving liver fat normalization to 5 percent or below [8]. Extension to 24 weeks produced 75.2 percent liver fat reduction at 1.8 mg and 6.2 percent body weight reduction versus placebo [7]. In the MOMENTUM trial, pemvidutide at 2.4 mg weekly for 48 weeks produced mean weight loss of 15.6 percent versus 2.2 percent on placebo, with body composition analysis demonstrating 78.1 percent of weight loss attributable to fat mass and 21.9 percent to lean mass [9, 10]. In the Phase 2b IMPACT trial (Noureddin et al. 2025) in 212 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, pemvidutide met the primary endpoint of MASH resolution without fibrosis worsening: 59.1 percent at 1.2 mg and 52.1 percent at 1.8 mg versus 19.1 percent for placebo (p < 0.0001 for both comparisons) [11]. Topline 48-week data demonstrated continued antifibrotic activity with statistically significant improvements in Enhanced Liver Fibrosis score and liver stiffness measurement versus placebo [12]. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for pemvidutide in MASH (January 2026) and Fast Track designations for both MASH and AUD [13, 14]. Phase 3 registrational programs for MASH and the VELOCITY Phase 3 program for obesity are in planning as of May 2026. Safety across completed trials has been favorable; adverse events are predominantly gastrointestinal (nausea, diarrhea, decreased appetite), mild to moderate in severity, and concentrated in the first 16 weeks of treatment. No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases have been observed. This monograph reviews the compound identification, structural pharmacology, mechanism of action, pharmacokinetics, preclinical and clinical evidence base, sourcing and quality verification, reconstitution and handling, stack interactions, adverse events, and a comparative assessment of five alternative agents (survodutide, semaglutide, tirzepatide, cotadutide, resmetirom) against pemvidutide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1410Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Ecnoglutide

Our opinion on this compoundNovel, promising

70/100

First cAMP-biased GLP-1RA with strong Phase 3 data and a genuinely novel receptor pharmacology story

Yeah, we’re interested in this one. Ecnoglutide is doing something the rest of the GLP-1 field hasn’t actually done yet: it was engineered from the ground up to be a biased agonist, not just a longer-acting peptide with a fancier linker. The Guo et al. (2023) characterization in XW003 is serious receptor pharmacology work. The key numbers are striking: full Gs/cAMP potency (EC50 0.018 nM, comparable to semaglutide), beta-arrestin Emax capped at roughly 54 to 60 percent of semaglutide, and receptor internalization EC50 pushed past 10 micromolar versus 0.093 micromolar for sema. That’s not a marginal difference. That’s a compound that essentially stays on the surface.

The mechanism rationale matters here. Beta-arrestin recruitment at GLP-1R is the canonical driver of receptor endocytosis and the tachyphylaxis observed with sustained agonist exposure. If you can preserve Gs/cAMP signaling while blunting the internalization arm, the theoretical outcome is a receptor that doesnt disappear from the cell surface under chronic dosing. Whether this translates clinically into meaningfully better efficacy per receptor occupancy or genuinely reduced GI burden is the open question. The Phase 3 SLIMMER data are real: 15.4 percent mean weight loss at 2.4 mg over 48 weeks, 92.8 percent of participants hitting 5 percent or greater. Those numbers are competitive with semaglutide in comparable populations. They’re not tirzepatide numbers, but thats a different mechanism class.

Here’s what we like about the evidence package: three Phase 3 trials, a genuine active comparator arm (EECOH-2 vs dulaglutide, 52 weeks), and NMPA approval in January 2026. For a compound that hasn’t touched FDA or EMA review yet, thats an unusual depth of controlled data. The HbA1c reductions in EECOH-1 are clinically meaningful, and the Phase 2 glycemic data are internally consistent with the Phase 3 readouts. The Ala8Val substitution also resolves the alpha-aminoisobutyric acid manufacturing issue that complicates semaglutide synthesis, which is a non-trivial advantage for research-grade sourcing and scale.

What holds ecnoglutide back from a higher placement is straightforward. It’s still one developer, one regulatory jurisdiction, no FDA or EMA file, and no head-to-head data showing that the biased pharmacology advantage is clinically detectable in a powered trial. The GLP-1 space is mature and crowded; tirzepatide and retatrutide are clearer bets on differentiated efficacy. Ecnoglutide’s real value for an investigator is precisely the biased-agonism probe utility: if you want to dissect which downstream effects at GLP-1R are Gs-driven versus beta-arrestin-driven in vivo, this is the compound you reach for. That’s genuine bench value. It’s just not category-defining on its own.

Novelty

70

Mechanism promise

78

In-category differentiation

60

Evidence quality

72

Translational signal

75

Research bench value

68

Rationale Ecnoglutide earns its score on the strength of a real mechanistic differentiator (cAMP-biased agonism with near-absent receptor internalization) and an unusual depth of Phase 3 evidence for a compound that only reached NMPA approval in January 2026; it falls short of the 80s because it occupies a well-funded GLP-1 space dominated by tirzepatide and retatrutide, its evidence base is single-developer and single-regulator, and the biased-agonism advantage over semaglutide has not yet been tested in a head-to-head clinical powered for differential tolerability.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

cAMP-biased glucagon-like peptide-1 receptor agonist with preferential Gs/cAMP signaling over beta-arrestin recruitment

A long-acting, fatty acid-conjugated GLP-1 analog developed at Sciwind Biosciences as the first cAMP signaling-biased GLP-1 receptor agonist, distinguished from semaglutide and other marketed incretin mimetics by selective activation of the Gs/adenylyl cyclase/cAMP cascade with markedly reduced beta-arrestin recruitment and GLP-1 receptor internalization, yielding sustained receptor surface availability and enhanced glycemic and weight-reducing efficacy in clinical populations.

Abstract

Ecnoglutide (XW003; CAS 2459531-73-6; molecular formula C194H304N48O61; molecular weight 4284.84 g/mol) is a lipopeptide analog of human glucagon-like peptide-1 (GLP-1) (7-37) engineered with an alanine-to-valine substitution at position 8 and a C18 fatty diacid conjugated to the epsilon-amino group of lysine 30 through a gamma-glutamate and dual 2-(2-(2-aminoethoxy)ethoxy)acetic acid linker. Designed and developed at Sciwind Biosciences (Hangzhou, China), ecnoglutide is the first GLP-1 receptor agonist intentionally optimized for cAMP signaling bias: it activates the Gs/adenylyl cyclase/cAMP cascade with an EC50 of 0.018 nM (comparable to semaglutide at 0.012 nM) while producing substantially reduced beta-arrestin recruitment (Emax approximately 54 to 60 percent of semaglutide, EC50 approximately 1300 nM) and negligible GLP-1 receptor internalization (EC50 greater than 10 micromolar versus 0.093 micromolar for semaglutide) [1]. The biased signaling profile preserves receptor surface density and downstream insulin secretion while reducing the desensitization, tachyphylaxis, and gastrointestinal adverse events theoretically attributable to beta-arrestin-mediated receptor endocytosis. In surface plasmon resonance binding studies, ecnoglutide demonstrates a dissociation constant (KD) of 1.45 nanomolar at the human GLP-1 receptor, approximately 10- to 30-fold higher affinity than semaglutide (KD 17.0 nanomolar) [1]. The compound consists exclusively of natural amino acids, simplifying the manufacturing process relative to semaglutide (which incorporates alpha-aminoisobutyric acid at position 8). Pharmacokinetics in healthy human volunteers support once-weekly subcutaneous dosing: the terminal elimination half-life at steady state ranges from 124 to 138 hours, with median time to peak concentration (Tmax) of 12 to 72 hours and dose-proportional plasma exposure across the studied dose range [1]. In the Phase 2 randomized, double-blind, placebo-controlled trial in 145 adults with type 2 diabetes, ecnoglutide at 0.4, 0.8, and 1.2 mg weekly for 20 weeks produced HbA1c reductions of 1.81, 1.90, and 2.39 percentage points, respectively, versus 0.55 points on placebo [2]. In the Phase 3 EECOH-1 trial of ecnoglutide monotherapy (0.6 mg and 1.2 mg weekly) in 211 patients with type 2 diabetes, up to 76.1 percent of patients in the 1.2 mg cohort achieved HbA1c targets of 6.5 percent or less [3]. In the Phase 3 EECOH-2 active-comparator trial, ecnoglutide 0.6 mg and 1.2 mg weekly demonstrated non-inferiority to dulaglutide 1.5 mg weekly on HbA1c reduction over 52 weeks, with the 1.2 mg dose achieving statistically significantly greater reduction [4]. In the Phase 3 SLIMMER trial in 664 adults with overweight or obesity without diabetes, ecnoglutide at 1.2, 1.8, and 2.4 mg weekly produced mean body weight reductions of 9.1, 10.9, and 13.2 percent, respectively, at 40 weeks versus 0.1 percent on placebo; at 48 weeks, the 2.4 mg dose achieved 15.4 percent mean weight loss, with 92.8 percent of participants achieving 5 percent or greater weight loss [5]. The safety profile is consistent with the GLP-1 receptor agonist class: the principal adverse events are gastrointestinal (nausea, diarrhea, decreased appetite), predominantly mild to moderate in severity, concentrated during the dose-escalation period, and diminishing over time. Hypoglycemia risk is low. China’s National Medical Products Administration (NMPA) approved ecnoglutide injection for chronic weight management in January 2026, making it the first approved cAMP-biased GLP-1 receptor agonist worldwide [6]. The compound is not approved by the United States Food and Drug Administration or by the European Medicines Agency as of the most recent monograph revision. This monograph reviews the chemistry, biased-agonist pharmacology, comprehensive pharmacokinetics, the clinical evidence base across type 2 diabetes and obesity indications, sourcing and quality considerations, reconstitution and handling, stack-interaction implications, adverse-event signal, and a comparative assessment of five GLP-1 receptor agonist and incretin mimetic candidates against ecnoglutide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1411Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026

←Previous Page

1 … 27 28 29 30 31 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.